JNJ - Embedded Expectations Analysis - 2021 05 21
Johnson & Johnson (JNJ:USA) currently trades near recent averages relative to UAFRS-based (Uniform) earnings, with a 16.9x Uniform P/E. At these levels, the market is pricing in expectations for profitability to remain stable, but management may have concerns about revenue growth, market share gains, and the potential of their R&D investmentsSpecifically, management may lack confidence in their ability to sustain growth in sequential net earnings, their electrophysiology (EP) business, and their international Oral Care and Baby Care businesses. Moreover, they may have concerns about the potential of their Medical Device business product launches, potential drug pricing reforms, and their vaccine's efficacy rate. Furthermore, management may lack confidence in their ability to grow the Orthopedics business, gain market share in the Vision Care business, and maintain share growth in DARZALEX therapy lines. In addition, management may be overstating the potential of their R&D investments, their focus on immunology business growth opportunities, and the capabilities of the Monarch platform. Finally, management may lack confidence in their ability to expand in the digital surgery market and maintain margin improvements in the Consumer Health segment
Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a range of products in the health care field. The company has three business segments: Consumer, which includes a range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension; and Medical Devices, which includes products used in the orthopaedic, surgery, interventional solutions, and eye health fields.
In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:
- GAAP and IFRS have failed to provide rules for reliable financial statement reporting
- Stock analyst recommendations are not grounded in disciplined financial analysis
- Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
- Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available
We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.
- Corporate credit ratings remain years behind the fundamental underpinnings of company performance
- Stock analysts continue to make recommendations with deeply inherent biases
- Research firms have failed to break down the walls between credit, equity, and macroeconomic research
- The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming
The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.